1[1]Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus[J]. N Engl J Med, 1999,340:493-501
2[2]Ubudata K, Nonoguchi R, Matsuhashi M. Expression and inducibility in Staphylococcus aureus of the mecA gene,which encodes a methicillin resistant staphylococcus aureus-specific penicillin-binding protein[J]. J Bacteriol, 1989, 171:2882-2885
3[3]Wood MJ. The comparative efficacy and safty of teicoplanin and vancomycin[J]. J Antimicrob Chemother, 1996, 37: 209-222
4[4]Richard P, Meyran M, Carpentier E, et al. Comparison of phenotypic methods and DNA hybridization for detection of methecillin-resistant Staphylococcus aureus[J]. J Clin Microbiol, 1994, 32 :613-617
5Performance standards for antimierobial susceptibility test[S].Ninth informance supplement, 2000. M100-S9.
6Krisher KK, Gibb P, Corbett S, et al. Comparison of the Bact/Alert PF pediatric FAN blood culture bottle with the standard pediatric blood culture bottle, the Pedi-Bact[J].J Clin Microbiol, 2001:39(8) :2880-2883.
7Bourbeau PP, Pohlman JK. Three days of incubation may be sufficient for routine blood cultures with Bact/Alert FAN blood culture bottles[J]. J Clin Microbiol, 2001,39 (6) : 2097-2O82.
8Soloaga R, Manganello S, Franeabandiera D, et al. Evaluation of the reineubation of positive blood culture for detection in the Baet/Alert system for the detection of polymicrobial baeteremia[J]. Rev Agent Mierobiol, 2000,32(1) :45-48.
9Borst A, Verhoef J, Boel E, et al. Clinical evaluation of a NASBA-based assay for deteetion of Candida spp. in blood and blood cultures[J]. Clin Lab, 2002,48(9-10):487-492.
10Santos Sanches I,Mato R,de Lencastre H, et al. Patterns of multidrug resistance among methicillin-resistant hospital isolates of coagnlase-positive and coagulase negative staphylococci collected in the international multicenter study RESIST in 1997 and 1998 [J]. Microbial Drug Resistance, 2000,6:199-211
3Boger DL. Vancomycin, teicoplanin, and ranmoplanin: synthetic and mechanistic studies[J]. Med Res Rev, 2001,21(5):856-381.
4Van der Auwera P, Aoun M, Meunier F. Randomised study of vancomycin versus teieoplanin for the treatment of Grampositive bacterial infections in immunoeompromised hosts[J]. Antimicrob Agents Chemother, 1991,35(3) :451-454.
5Pea F, Brollo L, Viale P, et al. Teicoplanin therapeutic drug monitoring in critically ill patients:a ret rospective study emphasizing the importance of a loading dose[J]. J Antimicrob Chemother,2003,51(4) :971-975.
6Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptidesor bata-lactam for treatment of Gram-positive bacterial infections :meta-analysis of randomized controlled trials〔J〕. Lancet Infect Dis,2008,8:53-66.
7Boselli E. Pharmacokinetics and intrapuimonary concentrations of line-zolid administered to critically ill patients with ventilator associatedpneumonia [j] . Crit Care Med, 2005, 33(7) : 1529-1533.
8Conte JE Jr. Intrapuimonary pharmacokinetics of linezolid〔J〕. An-timicrob Agents Chemother, 2002,46(5) : 175-1480.
9Garazzino S, De Rosa FG, Bargiacchi O, et al. Haematologicai satefy oflong-term theraphy with linezolid [J) . Int J Antimicrob Agents, 2007,29:480-483.
